[Featured Stock] SK Bioscience Rises on US Clinical Phase 3 Approval for Pneumococcal Vaccine

Up 4.24% Compared to Previous Close

SK Bioscience is showing strong performance in early trading on the 20th following news that it has received approval for the Phase 3 clinical trial plan of its 21-valent pneumococcal vaccine (GBP410) in the United States.

As of 10:09 AM on the same day, SK Bioscience is trading at 51,600 KRW, up 4.24% from the previous close.

On the 17th, SK Bioscience announced that it had received approval from the U.S. Food and Drug Administration (FDA) for the Phase 3 clinical trial plan of the 21-valent pneumococcal vaccine, which is being developed in collaboration with Sanofi. The global clinical trial, recruiting 7,700 participants worldwide, began dosing its first subject last month.